US2018256547A1PendingUtilityA1
Pyrazole-amide compounds and pharmaceutical use thereof
Est. expiryMar 15, 2033(~6.6 yrs left)· nominal 20-yr term from priority
A61P 43/00A61P 9/10A61P 9/06A61P 3/10A61P 9/12A61P 35/00A61P 9/04A61P 3/06A61P 9/00A61P 27/00A61P 27/12A61P 27/02A61P 3/04A61P 3/00A61P 11/00A61P 25/00A61P 13/12A61P 13/00C07D 231/12A61K 31/415C07C 69/78C07C 39/23
51
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
A compound represented by the following formula: wherein n is 1 or 2, or a pharmaceutically acceptable salt thereof, and a pharmaceutical use thereof.
Claims
exact text as granted — not AI-modified1 - 5 . (canceled)
6 . A method for the prophylaxis of diabetes, insulin resistance syndrome, metabolic syndrome, hyperglycemia, hyperlactacidemia, diabetic complications, cardiac failure, cardiomyopathy, myocardial ischemia, myocardial infarction, angina pectoris, dyslipidemia, atherosclerosis, peripheral arterial disease, intermittent claudication, chronic obstructive pulmonary disease, brain ischemia, cerebral apoplexy, mitochondrial disease, mitochondrial encephalomyopathy, cancer or pulmonary hypertension in a mammal, comprising administering to the mammal a pharmaceutically effective amount of a compound selected from the group consisting of:
i) a compound represented by formula [II]:
or a pharmaceutically acceptable salt thereof;
ii) a compound represented by formula [IIh]:
or a pharmaceutically acceptable salt thereof; and
iii) a compound represented by formula [III]:
or a pharmaceutically acceptable salt thereof.
7 . The method according to claim 6 , wherein the diabetes is type 1 diabetes or type 2 diabetes.
8 . The method according to claim 6 , wherein the diabetic complications are selected from the group consisting of diabetic neuropathy, diabetic retinopathy, diabetic nephropathy and cataract.
9 . The method according to claim 6 , wherein the cardiac failure is acute cardiac failure or chronic cardiac failure.
10 . The method according to claim 7 , wherein the diabetes is type 2 diabetes.
11 . The method according to claim 6 , wherein the compound is represented by the formula [II].
12 . The method according to claim 6 , wherein the compound is represented by the formula [IIh].
13 . The method according to claim 6 , wherein the compound is represented by the formula [III].Join the waitlist — get patent alerts
Track US2018256547A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.